Fenfluramine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Fenfluramine
- Fenfluramine: From Undocumented Original Indication to Proximal 16p11.2 Microdeletion Syndrome
Fenfluramine: From Undocumented Original Indication to Proximal 16p11.2 Microdeletion Syndrome
One-Sentence Summary
The evidence pack does not document fenfluramine’s original approved indication or mechanism of action. The TxGNN model predicts a possible association with proximal 16p11.2 microdeletion syndrome (score 99.93%), but zero clinical trials and zero publications currently support this direction, and the evidence pack’s own mechanistic review flags the prediction as likely knowledge-graph noise rather than a genuine repurposing signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack |
| Predicted New Indication | Proximal 16p11.2 microdeletion syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only, no trials or literature) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for fenfluramine is not available in this evidence pack (marked as a High-severity data gap, DG002). What can be extracted from the evidence pack’s own repurposing analysis is that fenfluramine acts as a serotonin releasing agent / reuptake inhibitor, with pharmacological activity centered on the appetite-regulation center and the 5-HT2C receptor.
Proximal 16p11.2 microdeletion syndrome, by contrast, is a structural chromosomal copy-number disorder presenting with developmental delay, obesity, and autism-spectrum features. Its pathophysiology stems from gene-dosage imbalance rather than a receptor or pathway that can be pharmacologically modulated. The evidence pack’s own mechanistic assessment explicitly concludes there is no direct mechanistic correspondence between fenfluramine’s serotonergic activity and the root cause of this syndrome, and suggests the high TxGNN score likely reflects an over-weighted “obesity/appetite phenotype” node association in the knowledge graph rather than a genuine therapeutic signal.
The remaining top-ranked candidates (hypervitaminosis, obsolete hypertelorism, frontorhiny) were assessed with the same conclusion — each lacks any plausible mechanistic pathway connecting fenfluramine’s known pharmacology to the candidate disease, and each is attributed to probable graph co-occurrence noise rather than biological plausibility. This pattern across all four top-ranked predictions is itself a notable finding and warrants review of the underlying prediction/ranking methodology before further evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
No India market authorizations found — fenfluramine is currently not marketed in India (total registrations: 0).
Safety Considerations
Drug Interactions: A DDI query returned 303 total interactions on record. Notable Major-severity interactions include:
- Fentanyl
- Dextromethorphan
- Tramadol
- Alfentanil
- Almotriptan
Additional Moderate-severity interactions include Abciximab, Abiraterone, Acalabrutinib, Acarbose, Dihydrocodeine, Codeine, Formoterol, Ketorolac, Trastuzumab emtansine, Ibuprofen, Albiglutide, Salbutamol, Ethanol, and Alogliptin/Pioglitazone, among others (303 total).
Label-level warnings and contraindications are not available in this evidence pack (data gap DG001, Blocking severity) — please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: All four top-ranked predicted indications are Evidence Level L5 (no clinical trials, no literature), and the evidence pack’s own mechanistic review concludes none of them have a plausible biological link to fenfluramine’s known pharmacology — the high TxGNN scores are assessed as likely artifacts of knowledge-graph co-occurrence rather than genuine repurposing signals. In addition, a Blocking-severity data gap (missing TFDA/label safety data) prevents even an initial S1 safety evaluation.
To proceed, the following is needed:
- TFDA (or relevant regulatory) package insert warnings/contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank or equivalent source (DG002, High)
- Documentation of fenfluramine’s original approved indication(s)
- Re-review of the TxGNN prediction/ranking methodology, given that all top 4 candidates were independently flagged as mechanistically implausible
- If lower-ranked candidates exist with stronger mechanistic rationale, prioritize those for evaluation instead
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.